Statistical comparison of the non-linear regressions showed differences between the responses induced by the two mAbs (P < 0.01; Fisher exact test).Please click here to view a larger version of this figure. Table 1. be Flurandrenolide extrapolated to other therapeutic mAbs. Keywords:Immunology, Issue 123, Rituximab, biosimilar, anti-CD20, therapeutic Rabbit Polyclonal to GHITM mAb, CDC, flow cytometry, Daudi cells Download video stream. == Introduction == Therapeutic antibodies are recombinant monoclonal antibodies (mAbs) developed for the treatment of different pathologies, including cancers, autoimmune and chronic diseases, neurologic disorders, and others1. Currently, the FDA has granted approval to more than 40 therapeutic mAbs, and more are expected to reach the market in the following years. Rituximab is a high-affinity chimeric monoclonal IgG1 antibody approved for the treatment of CD20+B-cell non-Hodgkin’s lymphoma (NHL), CD20+follicular NHL, chronic lymphocytic leukemia, and rheumatoid arthritis2,3. The recognition of CD20, which is overexpressed in B cells, by rituximab induces apoptosis; complement activation; and antibody-dependent cell mediated cytotoxicity (ADCC)3. The patents of this drug expired in Europe and in the U.S. in 2013 and 2016, respectively. Thus, pharmaceutical companies worldwide Flurandrenolide are developing rituximab biosimilars. As in any other drug for human consumption, biosimilars require approval from regulatory agencies. International guidelines indicate that for mAbs, biosimilarity should be demonstrated by comparing the physicochemical characteristics, pharmacokinetics, efficacy, and safety of the new and reference products4. Accordingly, the methodologies used in such comparisons must assess the structural and functional characteristics of the mAbs, especially those with clinical relevance. To that end,in vitroassays show several advantages overin vivoexperiments (reviewed in Chapmanet al.)5: i)in vitrostudies are more sensitive to differences between the proposed biosimilar and the reference product; ii)in vivostudies must be performed in relevant species, which for many mAbs are non-human primates; and iii) since the mechanism of action, the preclinical toxicology, and the clinical effects of the reference product are well known,in vivostudies with biosimilars may not provide additional useful information. Accordingly, the European Union’s Guidance for biosimilars allows candidates to enter clinical trials based on robustin vitrodata alone6. Here, we present two Flurandrenolide fast, economic, and simple assays that evaluate the biological activity of rituximab using CD20+cultured cells. These assays can be included as part of the comparability exercise for rituximab biosimilar candidates. == Protocol == == 1. Evaluation of Target Binding by Flow Cytometry == == 2. Assessment of CDC == == 3. Biosimilarity Analysis == Enter the concentration and response values into a graphing software. Generate graphs and calculate non-linear regressions with the following considerations: i) use the log-transformation of the mAb concentration as “X”; ii) use the variable slope mathematical model (Y = minimum response + (maximal response – minimum response)/ 1+10^((LogEC50-X)*Hill slope)); and iii) constrain the bottom values to zero, since the basal response has been subtracted. NOTE: Curves with a symmetrical sigmoidal shape are expected. Compare both nonlinear fits with a global fit using an F-test (many graphing software programs include this feature). NOTE: Such tests establish as the null hypothesis that the maximal response, logEC50, and the Hill slope are the same for the two datasets, which matches the biological question intended to be addressed. == Representative Results == Using the protocols described above, target binding and the CDC induction of reference rituximab were compared in parallel with those of a biosimilar rituximab produced and commercially available in Asia. In Daudi cells, both mAbs bound CD20 in a concentration-dependent manner (Figure 1D). Non-linear regressions of binding data displayed an r2of 0.978 and 0.848 for reference and biosimilar rituximab, Flurandrenolide respectively (Figure 1E). Statistical analysis of the concentration-response curves showed that they, and therefore the pharmacodynamic parameters calculated from them, are significantly different between mAbs (P < 0.0001). The maximal response for the biosimilar was 2.16-fold lower than that of the reference product. These results suggest that the two evaluated mAbs have different capacities to bind CD20 expressed on the membrane of leukemic cells. CDC induction was also compared to the two mAbs. Reference and biosimilar items activated CDC in Daudi cells within a concentration-dependent way (Amount 2E). Significantly, the concentrations of which the mAbs induced CDC had been unique of those necessary for focus on binding. nonlinear regressions from the CDC data demonstrated r2> 0.980 for both items. The statistical Flurandrenolide evaluation from the concentration-response curves indicated they are considerably different (P < 0.01), building the biosimilar less potent. These data suggest that the capability to induce CDC differs for the analyzed mAbs. Amount 1.In VitroTarget-binding of Anti-CD20 Therapeutic mAbs.Daudi GFP+cells were subjected to different concentrations from the mAbs (4.8 ng/mL to.